{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041299","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.152263+00:00","generated_at":"2026-06-11T18:32:42.928465+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Erasca Q2 2023 net loss $31.8M; cash $365.3M, funding into H2 2025","bullets":["Net loss of $31.8M ($0.21/ share) vs $35.6M ($0.30) in Q2 2022; R&D spend $26.2M.","Cash, equivalents, and marketable securities $365.3M as of Jun 30, 2023, down from $435.6M at Dec 31, 2022.","ERAS-007 Phase 1b in BRAFm CRC showed 50% (3/6) response rate; expansion data expected H2 2023–H1 2024.","First patient dosing in SEACRAFT-1 (naporafenib + trametinib) for RAS Q61X tumors expected H2 2023.","FDA granted Fast Track and Orphan Drug Designations for ERAS-801 in recurrent glioblastoma."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041299","json":"https://secwatch.observer/filing/0000950170-23-041299.json","markdown":"https://secwatch.observer/filing/0000950170-23-041299.md","text":"https://secwatch.observer/filing/0000950170-23-041299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023041299/0000950170-23-041299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023041299/eras-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:32:42.928465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec631b5da2fd4a990beb1c4d3f2b505b9a7e056b","claim":"Erasca, Inc. reported quarter ended June 30, 2023 results: net income Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023, EPS $(0.21).","evidence_excerpt":"Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023041299/0000950170-23-041299-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023"},{"label":"EPS","value":"$(0.21)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}